One-year outcomes in a multicentre cohort study of incident rare diffuse parenchymal lung disease in children (ChILD).
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 31748256.
- Also identified by DOI 10.1136/thoraxjnl-2019-213217.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We performed a prospective, observational, cohort study of children newly diagnosed with children's interstitial lung disease (ChILD), with structured follow-up at 4, 8, 12 weeks and 6 and 12 months. 127 children, median age 0.9 (IQR 0.3-7.9) years had dyspnoea (68%, 69/102), tachypnoea (75%, 77/103) and low oxygen saturation (SpO<sub>2</sub>) median 92% (IQR 88-96). Death (n=20, 16%) was the most common in those <6 months of age with SpO<sub>2</sub><94% and developmental/surfactant disorders. We report for the first time that ChILD survivors improved multiple clinical parameters within 8-12 weeks of diagnosis. These data can inform family discussions and support clinical trial measurements.
Medical subject headings
- Adrenal Cortex Hormones
- Azithromycin
- Hydroxychloroquine
- Lung Diseases, Interstitial